Skip to main content

RAPP-ID: Development of rapid point-of-care test platforms for infectious diseases

Excellent care for people with suspected infections involves rapid diagnosis and treatment. For instance, administering the correct antibiotic as soon as possible to patients with blood infections, dramatically improves their chances of survival. Equally so, using antibiotics when they do not benefit patients expose them unnecessarily to side effects and potential antibiotic resistance. In this modern age, we still do not have the technology available that can quickly diagnose what kind of infection and what treatment is needed. Even the best of the currently available diagnostic methods are too slow to help clinicians.

RAPP-ID logo

Excellent care for people with suspected infections involves rapid diagnosis and treatment. For instance, administering the correct antibiotic as soon as possible to patients with blood infections, dramatically improves their chances of survival. Equally so, using antibiotics when they do not benefit patients expose them unnecessarily to side effects and potential antibiotic resistance. In this modern age, we still do not have the technology available that can quickly diagnose what kind of infection and what treatment is needed. Even the best of the currently available diagnostic methods are too slow to help clinicians.

  • Blood infections,
  • Lower respiratory tract Infections, including community-acquired pneumonia and ventilator-associated pneumonia,
  • Tuberculosis

Detection of bacteria, fungi and antibiotic resistance will mainly involve Nucleic Acid tests, whereas viral and markers of infection detection will mainly involve selective immunobinding with a probe or with a sensor surface.

The diagnostic tests will consist of four functional modules: sample collection and interfacing; upconcentration and extraction; signal and/or sample amplification; and detection. RAPP-ID will integrate the modules required for each disease/syndrome in a matrix to be used with an instrument that reads the results, also developed within the project. The diagnostic platform will be validated on well-characterised clinical samples and compared with the best reference standards and other currently available diagnostic tests.

The RAPP-ID consortium draws its expertise from across Europe and includes 10 academic partners, 4 SMEs and 5 EFPIA companies who will work together over a 5-year period. 

MST contribution to RAPP-ID

An all OSTE RCA chip fabricated at MST. Collaboration between Uppsala University and MST, with original molds made by DTU, Denmark.
An all OSTE RCA chip fabricated at MST. Collaboration between Uppsala University and MST, with original molds made by DTU, Denmark.

In RAPP-ID MST brings its expertise in sample collection via electrohydrodynamic transport and transduction via QCMs, both developed in the RPA project and the novel polymer concept of off stoichiometry thiol-enes (OSTE).

The use of the OSTE family of polymers allows for research prototypes to be brought into medium to high volume production devices at an unprecedented speed, thanks to the similarities between specially formulated OSTE polymers and injection molding plastics such as COC (Cyclic Olefin Copolymer) and Polycarbonate in terms of mechanical and surface properties

Electrostatic flow is used to capture airborne pathogens onto a QCM transducer
Electrostatic flow is used to capture airborne pathogens onto a QCM transducer

RAPP-ID website

www.rapp-id.eu

Project members

Wouter van der Wijngaart

Tommy Haraldsson

Gaspard Pardon

Mikael Karlsson

Niklas Sandström

Project sponsor

  • European commission, 7th framework programme
  • EFPIA partners

Publications related to this project

Page responsible:Web editors at EECS
Belongs to: Micro and Nanosystems
Last changed: Dec 12, 2018